FindTrial
Sign In

SHR-A1904

DRUG5 trials

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., China Medical University, China

Conditions

Advanced Pancreatic CancerAdvanced Solid CancerAdvanced Solid TumorsCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionGastric CancerHER2 + Gastric CancerPD-L1 PositiveSecond-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 1

A Study of SHR-A1904 in Patients With Advanced Solid Cancer
Active, not recruitingNCT04877717
Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Cancer
Start: 2021-07-01End: 2025-12-01Updated: 2025-03-25
A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
NCT04928625
Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Pancreatic Cancer
Start: 2021-08-06End: 2023-12-31Target: 75Updated: 2021-08-24
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
RecruitingNCT05277168
Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors
Start: 2022-05-30End: 2026-05-30Target: 83Updated: 2026-01-02

Phase 2

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Not yet recruitingNCT06881017
China Medical University, ChinaCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer, HER2 + Gastric Cancer +1
Start: 2025-05-01End: 2029-11-01Target: 140Updated: 2025-03-18

Phase 3

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
RecruitingNCT06649292
Shanghai Hengrui Pharmaceutical Co., Ltd.Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Start: 2024-11-22End: 2028-03-20Target: 524Updated: 2024-12-12

Related Papers

The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.
2025-07-163 citations